| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Licarin B targets multiple pathways. It acts as a nitric oxide production inhibitor. It also targets PPARγ (peroxisome proliferator-activated receptor gamma), functioning as a partial agonist. By activating PPARγ, licarin B enhances the expression of GLUT4 (glucose transporter type 4) and improves insulin sensitivity in the IRS-1/PI3K/AKT signaling pathway. This dual mechanism contributes to its potential as a therapeutic agent for metabolic disorders.
|
|---|---|
| ln Vitro |
Licarin B (5 μM, 10 μM, and 15 μM. 8 days) has partial PPARg agonist action in 3T3-L1 preadipocytes and moderately enhances TG accumulation throughout adipogenic differentiation [2].
In vitro, licarin B inhibits nitric oxide production. In 3T3-L1 adipocytes, it improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway. These in vitro activities confirm its role as a partial PPARγ agonist and an insulin sensitizer. The compound's ability to modulate these pathways makes it a promising bioactive compound for insulin resistance research. |
| ln Vivo |
Detailed in vivo activity data for licarin B are not extensively provided in the search results. However, its in vitro effects on insulin sensitivity and PPARγ activation suggest potential for in vivo efficacy in models of diabetes and metabolic syndrome. Further studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
Non-cell-based assays for licarin B would typically involve measuring its ability to inhibit nitric oxide production in a cell-free system. This could be done using a nitric oxide donor and a chemiluminescence-based detection method. For PPARγ activity, a cell-free binding assay using the PPARγ ligand-binding domain and a fluorescently labeled ligand could be used.
|
| Cell Assay |
Cell viability assay[1]
Cell Types: 3T3-L1 cells. Tested Concentrations: 1-500 μM. Incubation Duration: 48 hrs (hours). Experimental Results: Concentrations up to 500 μM did not cause significant cell death. Cell viability assay[1] Cell Types: 3T3-L1 cells. Tested Concentrations: 5μM, 10μM, 15μM. Incubation Duration: 8 days (replace every 2 days). Experimental Results: LB at a concentration of 15 μM Dramatically promoted adipocyte differentiation and caused intracellular TG accumulation. Cellular assays for licarin B are performed using 3T3-L1 adipocytes. The cells are differentiated and treated with licarin B at various concentrations. The expression of PPARγ target genes, such as GLUT4, is measured by qPCR or Western blotting. Glucose uptake is measured using radiolabeled 2-deoxyglucose. Nitric oxide production is measured in stimulated cells using the Griess assay. These assays confirm the compound's insulin-sensitizing and anti-inflammatory effects. |
| Animal Protocol |
In vivo animal models for licarin B would likely involve the use of diet-induced obese (DIO) mice or genetically diabetic (db/db) mice. The compound would be administered orally, and its effects on blood glucose levels, insulin sensitivity, and glucose tolerance would be measured. These studies are crucial for evaluating the compound's potential as an anti-diabetic agent.
|
| ADME/Pharmacokinetics |
Licarin B has a molecular weight of 324.14 g/mol and a molecular formula of C20H20O4. It is a natural neolignan. It is soluble in DMSO. Detailed PK parameters such as half-life and bioavailability are not extensively detailed in the provided search results.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for licarin B are not provided in the search results. As a natural product, it is generally considered to have a good safety profile, but thorough toxicological studies would be required for therapeutic development. The compound is intended for research use only and is not for human consumption.
|
| References |
|
| Additional Infomation |
Licarin B has been reported in Aristolochia taliscana, Iryanthera lancifolia, and other organisms with available data. See also: (-)-Licarin B (note moved to).
Licarin B is a natural neolignan. It is a nitric oxide production inhibitor and improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway. It acts as a partial PPARγ agonist. It has the CAS number 51020-87-2 and is supplied for research purposes. |
| Molecular Formula |
C20H20O4
|
|---|---|
| Molecular Weight |
324.3704
|
| Exact Mass |
324.136
|
| CAS # |
51020-87-2
|
| PubChem CID |
6441061
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
428.5±45.0 °C at 760 mmHg
|
| Flash Point |
131.4±35.6 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.608
|
| LogP |
5.08
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
465
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C/C=C/C1=CC2=C(C(=C1)OC)O[C@H]([C@@H]2C)C3=CC4=C(C=C3)OCO4
|
| InChi Key |
DMMQXURQRMNSBM-YZAYTREXSA-N
|
| InChi Code |
InChI=1S/C20H20O4/c1-4-5-13-8-15-12(2)19(24-20(15)18(9-13)21-3)14-6-7-16-17(10-14)23-11-22-16/h4-10,12,19H,11H2,1-3H3/b5-4+/t12-,19-/m1/s1
|
| Chemical Name |
5-[(2R,3R)-7-methoxy-3-methyl-5-[(E)-prop-1-enyl]-2,3-dihydro-1-benzofuran-2-yl]-1,3-benzodioxole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~308.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.71 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0829 mL | 15.4145 mL | 30.8290 mL | |
| 5 mM | 0.6166 mL | 3.0829 mL | 6.1658 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0829 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
